Background: In 2018, the Clinical Microbiology Laboratory at our institution adopted updated daptomycin Methods: This mixed-methods study combined a clinician survey with a retrospective pre-post prescribing analysis. An 8-question survey was distributed to infectious diseases (ID) and internal medicine (IM) clinicians. A retrospective chart review of hospitalized adults with infections due to Results: Survey response rates were 40 of 98 (41%) for IM and 22 of 34 (65%) for ID clinicians. ID clinicians scored significantly higher than IM clinicians in knowledge of SDD. Chart review of 474 patients (225 pre- vs 249 post-SDD) showed that daptomycin dosage following susceptibility testing was significantly higher post-SDD compared with pre-SDD ...
Background: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-...
BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. ...
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections inc...
Enterococcus spp. are among the leading causes of nosocomial infections with growing resistance to s...
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimi...
Previous series on the use of daptomycin in enterococcal infective endocarditis (EIE) have shown var...
Infectious Diseases specialists have used high-dose daptomycin (≥6 mg/kg/day) in select patients wit...
We report a case series of 11 patients with severe E. faecium infections treated with daptomycin. Al...
We evaluated daptomycin activity trends against methicillin-resistant Staphylococcus aureus (MRSA) a...
This is the published version.Daptomycin is used off-label for enterococcal infections; however, dos...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90386/1/phco.31.7.665.pd
BACKGROUND: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faeci...
Background. Multi-drug resistant bacteria are a growing concern in healthcare. Daptomycin is being u...
ABSTRACTGram-positive infections, both community- and hospital-acquired, have a huge impact on healt...
Introduction: Daptomycin, a rapid concentration-dependent bactericidal antibiotic, is approved at a ...
Background: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-...
BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. ...
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections inc...
Enterococcus spp. are among the leading causes of nosocomial infections with growing resistance to s...
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimi...
Previous series on the use of daptomycin in enterococcal infective endocarditis (EIE) have shown var...
Infectious Diseases specialists have used high-dose daptomycin (≥6 mg/kg/day) in select patients wit...
We report a case series of 11 patients with severe E. faecium infections treated with daptomycin. Al...
We evaluated daptomycin activity trends against methicillin-resistant Staphylococcus aureus (MRSA) a...
This is the published version.Daptomycin is used off-label for enterococcal infections; however, dos...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90386/1/phco.31.7.665.pd
BACKGROUND: Daptomycin has become a front-line antibiotic for multidrug-resistant Enterococcus faeci...
Background. Multi-drug resistant bacteria are a growing concern in healthcare. Daptomycin is being u...
ABSTRACTGram-positive infections, both community- and hospital-acquired, have a huge impact on healt...
Introduction: Daptomycin, a rapid concentration-dependent bactericidal antibiotic, is approved at a ...
Background: Daptomycin is a cyclic lipopeptide with potent activity and broad spectrum against Gram-...
BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. ...
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections inc...